DE SB292 | 2021-2022 | 151st General Assembly
Status
Spectrum: Slight Partisan Bill (Democrat 20-9)
Status: Enrolled on June 30 2022 - 75% progression, died in chamber
Action: 2022-06-30 - Passed By House. Votes: 41 YES
Text: Latest bill text (Engrossed) [HTML]
Status: Enrolled on June 30 2022 - 75% progression, died in chamber
Action: 2022-06-30 - Passed By House. Votes: 41 YES
Text: Latest bill text (Engrossed) [HTML]
Summary
An opioid antagonist is a medication approved by the United States Food and Drug Administration (FDA) for emergency reversal of a known or suspected opioid overdose. Currently, naloxone is the only FDA-approved opioid antagonist, however, the FDA is expected to approve at least 1 new, more powerful opioid antagonist in 2022.
Title
An Act To Amend Title 16 Of The Delaware Code Relating To Naloxone And Other Opioid Antagonists.
Sponsors
Roll Calls
2022-06-30 - House - House Third Reading (Y: 41 N: 0 NV: 0 Abs: 0) [PASS]
2022-05-17 - Senate - Senate Third Reading (Y: 18 N: 0 NV: 0 Abs: 3) [PASS]
2022-05-17 - Senate - Senate Third Reading (Y: 18 N: 0 NV: 0 Abs: 3) [PASS]
History
| Date | Chamber | Action |
|---|---|---|
| 2022-06-30 | Passed By House. Votes: 41 YES | |
| 2022-06-15 | Reported Out of Committee (Health & Human Development) in House with 4 Favorable, 4 On Its Merits | |
| 2022-05-18 | Assigned to Health & Human Development Committee in House | |
| 2022-05-17 | Passed By Senate. Votes: 18 YES 3 ABSENT | |
| 2022-05-17 | Amendment SA 1 to SB 292 - Passed By Senate. Votes: 18 YES 3 ABSENT | |
| 2022-05-16 | Amendment SA 1 to SB 292 - Introduced and Placed With Bill | |
| 2022-05-11 | Reported Out of Committee (Health & Social Services) in Senate with 5 Favorable, 1 On Its Merits | |
| 2022-05-09 | Introduced and Assigned to Health & Social Services Committee in Senate |
